Jayashri Kulkarni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4251373/publications.pdf

Version: 2024-02-01

262 papers

12,358 citations

52 h-index 101 g-index

274 all docs

274 docs citations

times ranked

274

12337 citing authors

#	Article	IF	CITATIONS
1	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndromeâ€â€¡. Human Reproduction, 2018, 33, 1602-1618.	0.4	1,015
2	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 364-379.	0.5	759
3	Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research, 2000, 42, 241-247.	1.1	695
4	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 2016, 50, 410-472.	1.3	571
5	Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review. Schizophrenia Research and Treatment, 2012, 2012, 1-9.	0.7	441
6	Transcranial Magnetic Stimulation in the Treatment of Depression. Archives of General Psychiatry, 2003, 60, 1002.	13.8	340
7	A Randomized Trial of rTMS Targeted with MRI Based Neuro-Navigation in Treatment-Resistant Depression. Neuropsychopharmacology, 2009, 34, 1255-1262.	2.8	313
8	A Randomized, Controlled Trial of Sequential Bilateral Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression. American Journal of Psychiatry, 2006, 163, 88-94.	4.0	307
9	Estrogen — a potential treatment for schizophrenia. Schizophrenia Research, 2001, 48, 137-144.	1.1	236
10	An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Research - Neuroimaging, 2006, 148, 33-45.	0.9	214
11	Estrogen in Severe Mental Illness. Archives of General Psychiatry, 2008, 65, 955.	13.8	197
12	History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. Journal of Affective Disorders, 2007, 103, 181-186.	2.0	194
13	A clinical trial of the effects of estrogen in acutely psychotic women. Schizophrenia Research, 1996, 20, 247-252.	1.1	166
14	Intensity-dependent effects of 1 Hz rTMS on human corticospinal excitability. Clinical Neurophysiology, 2002, 113, 1136-1141.	0.7	162
15	An fMRI study of prefrontal brain activation during multiple tasks in patients with major depressive disorder. Human Brain Mapping, 2008, 29, 490-501.	1.9	156
16	Burnout and psychological distress amongst Australian healthcare workers during the COVID-19 pandemic. Australasian Psychiatry, 2021, 29, 26-30.	0.4	145
17	Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 2001, 103, 387-392.	2.2	144
18	Sex and gender differences in schizophrenic psychosesâ€"a critical review. Archives of Women's Mental Health, 2018, 21, 627-648.	1.2	140

#	Article	IF	CITATIONS
19	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry, 2015, 172, 743-750.	4.0	138
20	Coping styles and mental health in response to societal changes during the COVID-19 pandemic. International Journal of Social Psychiatry, 2021, 67, 540-549.	1.6	136
21	Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Molecular Psychiatry, 2015, 20, 695-702.	4.1	128
22	A Double-Blind Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in the Treatment of Refractory Auditory Hallucinations. Journal of Clinical Psychopharmacology, 2005, 25, 358-362.	0.7	127
23	A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression. Depression and Anxiety, 2009, 26, 229-234.	2.0	116
24	Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Molecular Psychiatry, 2015, 20, 685-694.	4.1	111
25	Reduced plastic brain responses in schizophrenia: a transcranial magnetic stimulation study*1. Schizophrenia Research, 2004, 71, 17-26.	1.1	107
26	A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology, 2006, 31, 543-547.	1.3	106
27	Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology, 2010, 35, 1142-1147.	1.3	106
28	Vestibular insights into cognition and psychiatry. Brain Research, 2013, 1537, 244-259.	1.1	101
29	A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2002, 114, 11-22.	0.9	98
30	Dehydroepiandrosterone Sulfate Levels Are Associated with More Favorable Cognitive Function in Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 801-808.	1.8	95
31	Translation and implementation of the Australianâ€led PCOS guideline: clinical summary and translation resources from the International Evidenceâ€based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Medical Journal of Australia, 2018, 209, S3-S8.	0.8	95
32	A systematic review of the impact of oral contraceptives on cognition. Contraception, 2014, 90, 111-116.	0.8	90
33	A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. International Journal of Neuropsychopharmacology, 2006, 9, 655.	1.0	81
34	Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology, 2017, 234, 3279-3297.	1.5	81
35	A Prospective Cohort Study of Antipsychotic Medications in Pregnancy: The First 147 Pregnancies and 100 One Year Old Babies. PLoS ONE, 2014, 9, e94788.	1.1	80
36	A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation, 2008, 1 , 27-32.	0.7	78

3

#	Article	IF	Citations
37	Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. Menopause, 2006, 13, 37-45.	0.8	76
38	The association between vasomotor symptoms and depression during perimenopause: A systematic review. Maturitas, 2014, 77, 111-117.	1.0	75
39	Priming Stimulation Enhances the Effectiveness of Low-Frequency Right Prefrontal Cortex Transcranial Magnetic Stimulation in Major Depression. Journal of Clinical Psychopharmacology, 2008, 28, 52-58.	0.7	74
40	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. JAMA Psychiatry, 2016, 73, 947.	6.0	74
41	Repetitive transcranial magnetic stimulation reveals abnormal plastic response to premotor cortex stimulation in schizophrenia. Biological Psychiatry, 2004, 56, 628-633.	0.7	73
42	Sex Differences and the Influence of Sex Hormones on Cognition through Adulthood and the Aging Process. Brain Sciences, 2018, 8, 163.	1.1	73
43	A study of transcallosal inhibition in schizophrenia using transcranial magnetic stimulation. Schizophrenia Research, 2002, 56, 199-209.	1.1	71
44	A Functional Magnetic Resonance Imaging Study of the Effects of Low Frequency Right Prefrontal Transcranial Magnetic Stimulation in Depression. Journal of Clinical Psychopharmacology, 2007, 27, 488-492.	0.7	70
45	Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: Maximal blunting in Kraepelinian patients. Biological Psychiatry, 1992, 32, 426-437.	0.7	66
46	Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?. Schizophrenia Research, 2011, 125, 278-283.	1.1	66
47	Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. Current Topics in Behavioral Neurosciences, 2010, 8, 155-171.	0.8	63
48	Victimization of Patients with Schizophrenia and Related Disorders. Australian and New Zealand Journal of Psychiatry, 2005, 39, 169-174.	1.3	62
49	Hormones and schizophrenia. Current Opinion in Psychiatry, 2012, 25, 89-95.	3.1	62
50	A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia. Psychopharmacology, 2002, 162, 74-81.	1.5	60
51	A longitudinal study of patient- and observer-rated quality of life in schizophrenia. Psychiatry Research, 2003, 119, 55-62.	1.7	58
52	Motor cortical excitability and clinical response to rTMS in depression. Journal of Affective Disorders, 2004, 82, 71-76.	2.0	57
53	Depression as a side effect of the contraceptive pill. Expert Opinion on Drug Safety, 2007, 6, 371-374.	1.0	56
54	Monitoring the Safe Use of Clozapine. CNS Drugs, 2007, 21, 117-127.	2.7	50

#	Article	IF	Citations
55	A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. Comprehensive Psychiatry, 2010, 51, 504-509.	1.5	48
56	Reduced neural activity of the prefrontal cognitive control circuitry during response inhibition to negative words in people with schizophrenia. Journal of Psychiatry and Neuroscience, 2012, 37, 379-388.	1.4	46
57	Antipsychotic use in pregnancy. Expert Opinion on Pharmacotherapy, 2015, 16, 1335-1345.	0.9	46
58	The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophrenia Research, 2018, 191, 61-69.	1,1	46
59	The treatment of recurring auditory hallucinations in schizophrenia with rTMS. World Journal of Biological Psychiatry, 2006, 7, 119-122.	1.3	45
60	Role of Estrogen Treatment in the Management of Schizophrenia. CNS Drugs, 2012, 26, 549-557.	2.7	44
61	Development of a Positive Body Image Chatbot (KIT) With Young People and Parents/Carers: Qualitative Focus Group Study. Journal of Medical Internet Research, 2021, 23, e27807.	2.1	44
62	A transcranial magnetic stimulation study of abnormal cortical inhibition in schizophrenia. Psychiatry Research, 2003, 118, 197-207.	1.7	43
63	The Role of Estrogen in the Treatment of Men with Schizophrenia. International Journal of Endocrinology and Metabolism, 2013, 11, 129-36.	0.3	43
64	Estrogen for schizophrenia. The Cochrane Library, 2005, , CD004719.	1.5	42
65	Estrogens and SERMS as adjunctive treatments for schizophrenia. Frontiers in Neuroendocrinology, 2019, 53, 100743.	2.5	42
66	Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause, 2006, 13, 600-608.	0.8	41
67	Hormone Modulation: A Novel Therapeutic Approach for Women with Severe Mental Illness. Australian and New Zealand Journal of Psychiatry, 2008, 42, 83-88.	1.3	41
68	Funding for mental health research: the gap remains. Medical Journal of Australia, 2011, 195, 681-684.	0.8	40
69	Preliminary Findings from the National Register of Antipsychotic Medication in Pregnancy. Australian and New Zealand Journal of Psychiatry, 2008, 42, 38-44.	1.3	39
70	Gender-Sensitive Mental Health Care. Australasian Psychiatry, 2009, 17, 105-111.	0.4	39
71	Sex and gender in health research: updating policy to reflect evidence. Medical Journal of Australia, 2020, 212, 57.	0.8	39
72	Antipsychotics in pregnancy. Journal of Psychiatric and Mental Health Nursing, 2010, 17, 97-104.	1.2	38

#	Article	IF	CITATIONS
73	Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas, 2012, 73, 127-133.	1.0	37
74	Complex PTSD $\hat{a}\in$ a better description for borderline personality disorder? Australasian Psychiatry, 2017, 25, 333-335.	0.4	37
75	Home-oriented management programme for people with early psychosis. British Journal of Psychiatry, 1998, 172, 39-44.	1.7	36
76	Testosterone Improves Antidepressant-Emergent Loss of Libido in Women: Findings from a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Sexual Medicine, 2014, 11, 831-839.	0.3	36
77	Naturalistic Study of the use of Transcranial Magnetic Stimulation in the Treatment of Depressive Relapse. Australian and New Zealand Journal of Psychiatry, 2006, 40, 764-768.	1.3	35
78	A preliminary fMRI study of the effects on cortical activation of the treatment of refractory auditory hallucinations with rTMS. Psychiatry Research - Neuroimaging, 2007, 155, 83-88.	0.9	35
79	What factors determine whether a woman becomes depressed during the perimenopause?. Archives of Women's Mental Health, 2012, 15, 323-332.	1.2	34
80	What is needed to deliver collaborative care to address comorbidity more effectively for adults with a severe mental illness?. Australian and New Zealand Journal of Psychiatry, 2013, 47, 333-346.	1.3	34
81	A study of the effects of lorazepam and dextromethorphan on the response to cortical 1 Hz repetitive transcranial magnetic stimulation. NeuroReport, 2005, 16, 1525-1528.	0.6	33
82	Effects of Oral Contraceptive Androgenicity on Visuospatial and Social-Emotional Cognition: A Prospective Observational Trial. Brain Sciences, 2020, 10, 194.	1.1	33
83	Oestrogen — a new treatment approach for schizophrenia?. Medical Journal of Australia, 2009, 190, S37-8.	0.8	32
84	A study of the effectiveness of high-frequency left prefrontal cortex transcranial magnetic stimulation in major depression in patients who have not responded to right-sided stimulation. Psychiatry Research, 2009, 169, 12-15.	1.7	32
85	Coronary Heart Disease Risk Reduction Intervention Among Overweight Smokers with a Psychotic Disorder: Pilot Trial. Australian and New Zealand Journal of Psychiatry, 2009, 43, 129-135.	1.3	31
86	Challenges Relating to the Interface Between Crisis Mental Health Clinicians and Police When Engaging with People with a Mental Illness. Psychiatry, Psychology and Law, 2012, 19, 402-411.	0.9	31
87	The influence of endogenous estrogen on transcranial direct current stimulation: A preliminary study. European Journal of Neuroscience, 2018, 48, 2001-2012.	1.2	31
88	Factors Associated with Depression During the Perimenopausal Transition. Women's Health Issues, 2013, 23, e301-e307.	0.9	30
89	Impact of comorbid anxiety disorders and obsessive–compulsive disorder on 24-month clinical outcomes of bipolar I disorder. Journal of Affective Disorders, 2014, 166, 243-248.	2.0	29
90	Psychiatrist burnout: a meta-analysis of Maslach Burnout Inventory means. Australasian Psychiatry, 2019, 27, 249-254.	0.4	29

#	Article	IF	Citations
91	The Role of Oestrogen and Other Hormones in the Pathophysiology and Treatment of Schizophrenia. Schizophrenia Research and Treatment, 2012, 2012, 1-8.	0.7	28
92	Estrogen affects cognition in women with psychosis. Psychiatry Research, 2000, 94, 201-209.	1.7	27
93	Depressive, positive, negative and parkinsonian symptoms in schizophrenia. Australian and New Zealand Journal of Psychiatry, 2002, 36, 340-346.	1.3	27
94	A confirmatory factor analytic evaluation of the pentagonal PANSS model. Schizophrenia Research, 2003, 61, 97-104.	1.1	27
95	Consumer perspectives on the therapeutic value of a psychiatric environment. Journal of Mental Health, 2015, 24, 63-67.	1.0	27
96	Tibolone improves depression in women through the menopause transition: A double-blind randomized controlled trial of adjunctive tibolone. Journal of Affective Disorders, 2018, 236, 88-92.	2.0	27
97	Women and Schizophrenia: A Review. Australian and New Zealand Journal of Psychiatry, 1997, 31, 46-56.	1.3	26
98	A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology, 2014, 43, 52-61.	1.3	26
99	Major depression and electrovestibulography. World Journal of Biological Psychiatry, 2015, 16, 334-350.	1.3	26
100	The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Human Psychopharmacology, 2003, 18, 551-557.	0.7	25
101	A prospective study of the impact of subthreshold mixed states on the 24-month clinical outcomes of bipolar I disorder or schizoaffective disorder. Journal of Affective Disorders, 2010, 124, 22-28.	2.0	25
102	Menstrual cycle characteristics in women with persistent schizophrenia. Australian and New Zealand Journal of Psychiatry, 2016, 50, 481-487.	1.3	25
103	Adjunctive raloxifene for postmenopausal women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophrenia Research, 2018, 197, 288-293.	1.1	25
104	Systematic review and meta-analysis of basal cortisol levels in Borderline Personality Disorder compared to non-psychiatric controls. Psychoneuroendocrinology, 2019, 102, 149-157.	1.3	25
105	Disordered Eating Behaviours and Eating Disorders in Women in Australia with and Without Polycystic Ovary Syndrome: A Cross-Sectional Study. Journal of Clinical Medicine, 2019, 8, 1682.	1.0	24
106	The influence of endogenous estrogen on high-frequency prefrontal transcranial magnetic stimulation. Brain Stimulation, 2019, 12, 1271-1279.	0.7	24
107	Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Biological Psychiatry, 1990, 27, 1203-1215.	0.7	23
108	Development and validation of a new rating scale for perimenopausal depressionâ€"the Meno-D. Translational Psychiatry, 2018, 8, 123.	2.4	23

#	Article	IF	CITATIONS
109	The impact of age at onset of bipolar I disorder on functioning and clinical presentation. Acta Neuropsychiatrica, 2009, 21, 191-196.	1.0	22
110	A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study. Canadian Journal of Psychiatry, 2009, 54, 46-54.	0.9	22
111	Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder. Psychiatry Investigation, 2015, 12, 349.	0.7	22
112	Problem gambling and substance use in patients attending community mental health services. Journal of Behavioral Addictions, 2017, 6, 678-688.	1.9	22
113	The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders. Medical Journal of Australia, 2017, 206, 501-505.	0.8	22
114	Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status. Psychoneuroendocrinology, 2019, 100, 113-119.	1.3	22
115	Measuring Quality of Life in Female Genital Cosmetic Procedure Patients: A Systematic Review of Patient-Reported Outcome Measures. Aesthetic Surgery Journal, 2020, 40, 311-318.	0.9	22
116	Managing Psychosis in Pregnancy. Australian and New Zealand Journal of Psychiatry, 2007, 41, 289-292.	1.3	21
117	Dopamine uptake by platelets from subjects with schizophrenia: A correlation with the delusional state of the patient. Psychiatry Research, 1992, 41, 17-24.	1.7	20
118	Extrapyramidal symptoms and oestrogen. Acta Psychiatrica Scandinavica, 2000, 101, 130-134.	2.2	20
119	Significant differences in fMRI related activity between healthy adults and people with schizophrenia during reward-related prediction-errors. Molecular Psychiatry, 2012, 17, 235-235.	4.1	20
120	Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry, 2012, 12, 228.	1.1	20
121	Menstrual cycle irregularity and menopause status influence cognition in women with schizophrenia. Psychoneuroendocrinology, 2018, 96, 173-178.	1.3	20
122	<p>Borderline personality disorder, trauma, and the hypothalamus–pituitary–adrenal axis</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2601-2612.	1.0	20
123	The Cost of Relapse in Schizophrenia and Schizoaffective Disorder. Australasian Psychiatry, 2009, 17, 265-272.	0.4	19
124	Promoting recovery via an integrated model of care to deliver a bed-based, mental health prevention and recovery centre. Australasian Psychiatry, 2014, 22, 481-488.	0.4	19
125	Do mental health clinicians elicit a history of previous trauma in female psychiatric inpatients?. Journal of Mental Health, 2016, 25, 359-365.	1.0	19
126	Do Genital Cosmetic Procedures Improve Women's Self-Esteem? A Systematic Review and Meta-Analysis. Aesthetic Surgery Journal, 2020, 40, 1143-1151.	0.9	19

#	Article	IF	CITATIONS
127	Impact of irritability: a 2â€year observational study of outpatients with bipolar I or schizoaffective disorder. Bipolar Disorders, 2017, 19, 184-197.	1.1	18
128	Sex differences in cognition and aging and the influence of sex hormones. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 175, 103-115.	1.0	18
129	Perimenopausal depression - an under-recognised entity. Australian Prescriber, 2018, 41, 183-185.	0.5	18
130	Mental health care on the streets: An integrated approach. Australian and New Zealand Journal of Psychiatry, 2010, 44, 505-12.	1.3	18
131	Effects of rTMS on an Auditory Oddball Task: A Pilot Study of Cortical Plasticity and the EEG. Clinical EEG and Neuroscience, 2008, 39, 139-143.	0.9	17
132	Oestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response?. International Journal of Neuropsychopharmacology, 2011, 14, 553-566.	1.0	17
133	Gender differences in characteristics and outcomes of smokers diagnosed with psychosis participating in a smoking cessation intervention. Psychiatry Research, 2014, 215, 586-593.	1.7	17
134	Bipolar disorder in the balance. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 761-775.	1.8	17
135	Psychiatric comorbidities and adverse childhood experiences in women with self-reported polycystic ovary syndrome: An Australian population-based study. Psychoneuroendocrinology, 2020, 116, 104678.	1.3	17
136	Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian and New Zealand Journal of Psychiatry, 2022, 56, 230-247.	1.3	17
137	Health behaviour risk factors for coronary heart disease (CHD) in smokers with a psychotic disorder: baseline results. Mental Health and Substance Use: Dual Diagnosis, 2011, 4, 158-171.	0.5	16
138	The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 2013, 146, 146-149.	2.0	16
139	Quality of life in bipolar and schizoaffective disorder â€" A naturalistic approach. Comprehensive Psychiatry, 2014, 55, 1540-1545.	1.5	16
140	The unique symptom profile of perimenopausal depression. Clinical Psychologist, 2015, 19, 76-84.	0.5	16
141	Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial. CNS Drugs, 2018, 32, 179-187.	2.7	16
142	Hormonal contraception and mood disorders. Australian Prescriber, 2022, 45, 75-79.	0.5	16
143	Relationship of psychotic symptoms to haloperidolâ€stimulated prolactin release. Acta Psychiatrica Scandinavica, 1990, 82, 271-274.	2.2	15
144	Transitioning patients taking clozapine from the public to private/GP shared-care setting: Barriers and criteria. Australian and New Zealand Journal of Psychiatry, 2012, 46, 225-231.	1.3	15

#	Article	IF	Citations
145	Sensitivity, specificity, and predictive power of the "Brief Riskâ€resilience Index for SC reening,―a brief panâ€diagnostic web screen for emotional health. Brain and Behavior, 2012, 2, 576-589.	1.0	15
146	Perinatal Mental Health in Women with Polycystic Ovary Syndrome: A Cross-Sectional Analysis of an Australian Population-Based Cohort. Journal of Clinical Medicine, 2019, 8, 2070.	1.0	15
147	Family Violence: An Insight Into Perspectives and Practices of Australian Health Practitioners. Journal of Interpersonal Violence, 2021, 36, NP2391-NP2409.	1.3	15
148	A network meta-analysis of stress mediators in suicide behaviour. Frontiers in Neuroendocrinology, 2021, 63, 100946.	2.5	15
149	Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey. Neuropsychiatric Disease and Treatment, 2013, 9, 1163.	1.0	14
150	Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale. Journal of Evaluation in Clinical Practice, 2012, 18, 360-364.	0.9	13
151	The perceived risks and benefits of quitting in smokers diagnosed with severe mental illness participating in a smoking cessation intervention: Gender differences and comparison to smokers without mental illness. Drug and Alcohol Review, 2014, 33, 78-85.	1.1	13
152	Establishing female-only areas in psychiatry wards to improve safety and quality of care for women. Australasian Psychiatry, 2014, 22, 551-556.	0.4	13
153	Sex hormones and cognition in aging. Vitamins and Hormones, 2021, 115, 511-533.	0.7	13
154	Depression associated with combined oral contraceptives—a pilot study. Australian Family Physician, 2005, 34, 990.	0.5	13
155	Australian Schizophrenia Care and Assessment Programme: Real-World Schizophrenia: Economics. Australian and New Zealand Journal of Psychiatry, 2007, 41, 819-829.	1.3	12
156	The Bipolar Comprehensive Outcomes Study (BCOS): Baseline findings of an Australian cohort study. Journal of Affective Disorders, 2008, 107, 135-144.	2.0	12
157	Estradiol treatment and its interaction with the cholinergic system: Effects on cognitive function in healthy young women. Hormones and Behavior, 2008, 54, 684-693.	1.0	12
158	Predictors of Perceived Coercion in Patients Admitted for Psychiatric Hospitalization and the Stability of these Perceptions over Time. Psychiatry, Psychology and Law, 2013, 20, 492-503.	0.9	12
159	An update on medication management of women with schizophrenia in pregnancy. Expert Opinion on Pharmacotherapy, 2019, 20, 1365-1376.	0.9	12
160	Treatment of schizophrenia. Medical Journal of Australia, 1989, 151, 462-467.	0.8	12
161	Special issues in managing long-term mental illness in women. International Review of Psychiatry, 2010, 22, 183-190.	1.4	11
162	Special biological issues in the management of women with schizophrenia. Expert Review of Neurotherapeutics, 2012, 12, 823-833.	1.4	10

#	Article	IF	Citations
163	Evidence for a differential contribution of early perceptual and late cognitive processes during encoding to episodic memory impairment in schizophrenia. World Journal of Biological Psychiatry, 2017, 18, 369-381.	1.3	10
164	Improvement in depression with oestrogen treatment in women with schizophrenia. Archives of Women's Mental Health, 2020, 23, 149-154.	1.2	10
165	Pilot Data on the Feasibility And Clinical Outcomes of a Nomegestrol Acetate Oral Contraceptive Pill in Women With Premenstrual Dysphoric Disorder. Frontiers in Endocrinology, 2021, 12, 704488.	1.5	10
166	Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. Psychoneuroendocrinology, 1990, 15, 225-231.	1.3	9
167	Oestrogen-A Protective Factor in Schizophrenia?. Current Psychiatry Reviews, 2006, 2, 339-352.	0.9	9
168	The role of pharmacogenomic testing in psychiatry: Real world examples. Australian and New Zealand Journal of Psychiatry, 2014, 48, 778-778.	1.3	9
169	Inpatient views and experiences before and after implementing a totally smokeâ€free policy in the acute psychiatry hospital setting. International Journal of Mental Health Nursing, 2015, 24, 350-359.	2.1	9
170	Psychiatrists' awareness of partial- and non-adherence to antipsychotic medication in schizophrenia: results from the Australian ADHES survey. Australasian Psychiatry, 2015, 23, 258-264.	0.4	9
171	Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia. Psychiatry Research, 2019, 280, 112510.	1.7	9
172	Sex Differences in Aging and Associated Biomarkers. Advances in Experimental Medicine and Biology, 2019, 1178, 57-76.	0.8	9
173	Vulnerable populations and multicentred research. International Journal of Mental Health Nursing, 2009, 18, 108-115.	2.1	8
174	Raloxifene for schizophrenia and symptoms of hyperprolactinaemia?. Australian and New Zealand Journal of Psychiatry, 2017, 51, 294-294.	1.3	8
175	Improving safety for women in psychiatry wards. Australian and New Zealand Journal of Psychiatry, 2017, 51, 192-194.	1.3	8
176	Borderline personality disorder and polycystic ovary syndrome: A review of the literature. Australian and New Zealand Journal of Psychiatry, 2018, 52, 117-128.	1.3	8
177	Ondansetron – a promising adjunctive treatment for persistent schizophrenia. Journal of Psychopharmacology, 2018, 32, 1204-1211.	2.0	8
178	Bazedoxifene – a promising brain active SERM that crosses the blood brain barrier and enhances spatial memory. Psychoneuroendocrinology, 2020, 121, 104830.	1.3	8
179	Disordered eating and the meat-avoidance spectrum: a systematic review and clinical implications. Eating and Weight Disorders, 2022, 27, 2347-2375.	1.2	8
180	The Medical and Psychological Investigation of Psychogenic Polydipsia: A Case Study. British Journal of Psychiatry, 1985, 146, 545-547.	1.7	7

#	Article	IF	CITATIONS
181	Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease. Biological Psychiatry, 1992, 31, 1225-1227.	0.7	7
182	Brain Activation During Affective Visual Cues in Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 450-452.	0.7	7
183	Australian Schizophrenia Care and Assessment Programme: Real-World Schizophrenia: Outcomes. Australian and New Zealand Journal of Psychiatry, 2007, 41, 969-979.	1.3	7
184	Primary healthcare practitioners' screening practices and attitudes towards women survivors of child abuse. Mental Health in Family Medicine, 2012, 9, 181-9.	0.2	7
185	Psychotic women can estimate menstrual cycle phase as well as controls. Schizophrenia Research, 1997, 23, 185-186.	1.1	6
186	EVestGâ,,¢: A diagnostic measure for schizophrenia. , 2008, 2008, 4142-5.		6
187	Sequential behavioral treatment of smoking and weight control in bipolar disorder. Translational Behavioral Medicine, 2012, 2, 290-295.	1.2	6
188	To a broader concept of remission: Rating the health-related quality of life in bipolar disorder. Journal of Affective Disorders, 2013, 150, 673-676.	2.0	6
189	Demonstrating the effectiveness of less restrictive care pathways for the management of patients treated with clozapine. Australasian Psychiatry, 2013, 21, 449-455.	0.4	6
190	Mental health: outcomes of 10 babies of mothers with a history of serious mental illness. Journal of Psychiatric and Mental Health Nursing, 2014, 21, 580-586.	1.2	6
191	The 2016 RANZCP Guidelines for the Management of Schizophrenia and Related Disorders – what's next?. Australasian Psychiatry, 2017, 25, 600-602.	0.4	6
192	Serum estradiol as a blood-based biomarker predicting hormonal treatment outcomes in women with schizophrenia. Psychoneuroendocrinology, 2021, 126, 105165.	1.3	6
193	Risk Factors for Depression During Perimenopause. , 2014, , 215-233.		6
194	The prevalence of early life trauma in premenstrual dysphoric disorder (PMDD). Psychiatry Research, 2022, 308, 114381.	1.7	6
195	Validation of a method to measure the uptake of [3H]dopamine by human platelets. Clinica Chimica Acta, 1990, 187, 37-46.	0.5	5
196	Women's Mental Health. Australian and New Zealand Journal of Psychiatry, 2008, 42, 1-2.	1.3	5
197	Breastfeeding and psychotropic medications. Lancet, The, 2013, 381, 905.	6.3	5
198	Perspectives on the Mental Health Act 2014 (Vic). Australasian Psychiatry, 2014, 22, 569-572.	0.4	5

#	Article	IF	CITATIONS
199	Psychosis induced by antidepressant treatment with reboxetine. Australian and New Zealand Journal of Psychiatry, 2019, 53, 1227-1228.	1.3	5
200	Using accelerometer as a diagnostic tool to detect drug-induced parkinsonism (DIP) secondary to first-generation anti-psychotic medications. Australasian Psychiatry, 2020, 28, 348-353.	0.4	5
201	Trauma-informed sentencing of serious violent offenders: an exploration of judicial dispositions with a gendered perspective. Psychiatry, Psychology and Law, 2021, 28, 748-773.	0.9	5
202	Improving the detection and treatment of depression in Australians with multiple sclerosis: A qualitative analysis. Multiple Sclerosis and Related Disorders, 2021, 56, 103290.	0.9	5
203	Women survivors of child abuse - don't ask, don't tell. Australian Family Physician, 2012, 41, 903-6.	0.5	5
204	Symptomatic Response to Antipsychotics Differs between Recent Onset and Recurrent Chronic Schizophrenic Patients. Australian and New Zealand Journal of Psychiatry, 1992, 26, 417-422.	1.3	4
205	Basal and haloperidol-stimulated prolactin and symptoms of nonaffective and affective psychoses in neuroleptic-free men. Biological Psychiatry, 1995, 37, 229-234.	0.7	4
206	Gestational diabetes in women with mental illness. Australian and New Zealand Journal of Psychiatry, 2014, 48, 958-958.	1.3	4
207	Women's mental health: Still not a priority, still not good enough. Australian and New Zealand Journal of Psychiatry, 2014, 48, 701-704.	1.3	4
208	Retrospective audit of people treated with long-acting antipsychotic injectable medications: Usage patterns and outcomes. Schizophrenia Research, 2018, 197, 572-573.	1.1	4
209	How self-inflicted injury and gender impacted the outcome following a severe burn. Burns, 2019, 45, 621-626.	1.1	4
210	Eating disorders and meat avoidance: A call to understand the †why†instead of the †whatâ€. Australian and New Zealand Journal of Psychiatry, 2022, 56, 731-732.	1.3	4
211	Road testing the newer antipsychotic agents. Australian Family Physician, 2006, 35, 96-9.	0.5	4
212	Growth hormone response to clonidine in neuroleptic-free patients with multidiagnostically defined schizophrenia. Psychiatry Research, 1993, 48, 79-90.	1.7	3
213	Gonadotropin response to naloxone challenge in female and male psychotic patients: A pilot study. Biological Psychiatry, 1995, 38, 701-703.	0.7	3
214	Clinical Estrogen Trials in Patients with Schizophrenia., 2005,, 107-122.		3
215	Suicide rates and mental health disorder prevention. Australian and New Zealand Journal of Psychiatry, 2015, 49, 91-92.	1.3	3
216	Tibolone treatment for perimenopausal depression: Three cases. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1213-1214.	1.3	3

#	Article	IF	Citations
217	Australian Junior Doctors' Perspectives on Psychiatry Teaching in Medical School. Academic Psychiatry, 2020, 44, 562-565.	0.4	3
218	Influence of cortisol awakening response on telomere length: Trends for males and females. European Journal of Neuroscience, 2022, 55, 2794-2803.	1.2	3
219	Revisiting the effectiveness of repetitive transcranial magnetic stimulation treatment in depression, again. Australian and New Zealand Journal of Psychiatry, 2022, 56, 905-909.	1.3	3
220	Oestrogen and Neuroprotection. Australian and New Zealand Journal of Psychiatry, 2011, 45, 596-596.	1.3	2
221	Psychosis in Women. , 2013, , 1283-1291.		2
222	A case of perimenopausal depression. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1109-1109.	1.3	2
223	Borderline personality disorder and polycystic ovary syndrome. Australian and New Zealand Journal of Psychiatry, 2016, 50, 385-385.	1.3	2
224	Oestradiol treatment for mood stabilisation in borderline personality disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 739-739.	1.3	2
225	Re-framing borderline personality disorder. Australasian Psychiatry, 2020, 28, 237-238.	0.4	2
226	Assessment and treatment of depression in people with multiple sclerosis: A qualitative analysis of specialist clinicians' experiences. Multiple Sclerosis and Related Disorders, 2022, 57, 103362.	0.9	2
227	Measuring posttraumatic stress disorder following childbirth. Australasian Psychiatry, 2022, , 103985622210779.	0.4	2
228	Menstrual Cycle in Trauma-Related Disorders: A Mini-Review. Frontiers in Global Women S Health, 0, 3,	1.1	2
229	Women's mental health: an overview. Women's Health Medicine, 2006, 3, 55-58.	0.0	1
230	Quantitative detection and assessment of schizophrenia using electrovestibulography., 2009,,.		1
231	Female sexual dysfunction in psychiatry. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1193-1194.	1.3	1
232	Travel advice for patients with psychotic disorders. Australian and New Zealand Journal of Psychiatry, 2014, 48, 687-687.	1.3	1
233	Special issues for women with mental issues during pregnancy and beyond. Australian and New Zealand Journal of Psychiatry, 2014, 48, 880-880.	1.3	1
234	Paradoxical hypersexuality in depression. Australian and New Zealand Journal of Psychiatry, 2015, 49, 297-298.	1.3	1

#	Article	IF	CITATIONS
235	Surveillance of hyponatremia in psychogenic polydipsia. Australian and New Zealand Journal of Psychiatry, 2015, 49, 392-393.	1.3	1
236	Hormones and Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 463-480.	0.7	1
237	First episode psychosis in an adult patient with tuberous sclerosis. Australian and New Zealand Journal of Psychiatry, 2016, 50, 292-293.	1.3	1
238	The borderline paradox. Australian and New Zealand Journal of Psychiatry, 2017, 51, 537-537.	1.3	1
239	T249. THE ROYAL AUSTRALIAN AND NEW ZEALAND CLINICAL PRACTICE GUIDELINES FOR SCHIZOPHRENIA AND RELATED DISORDERS (2016) – A STEP TOWARDS BETTER CARE?. Schizophrenia Bulletin, 2018, 44, S214-S214.	2.3	1
240	Complex post-traumatic stress disorder and pre-menstrual dysphoric disorder. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110256.	1.3	1
241	Naturalistic Study of the use of Transcranial Magnetic Stimulation in the Treatment of Depressive Relapse. , 0, .		1
242	The clinical needs of women with schizophrenia. , 2012, , 183-201.		1
243	Biological basis of sex differences in psychopharmacology. Preface. Current Topics in Behavioral Neurosciences, 2011, 8, v-vii.	0.8	1
244	Sample bias in neurobiological studies of neuroleptic-naive psychotic subjects. Schizophrenia Research, 1991, 4, 260-261.	1.1	0
245	Platelet [3H] dopamine uptake in patients with schizophrenia and non-schizophrenic psychoses: Its relationship to psychopathology. Schizophrenia Research, 1991, 4, 343.	1.1	O
246	The effects of adjunctive estradiol on cognitive performance in women with schizophrenia. Acta Neuropsychiatrica, 2006, 18, 257-258.	1.0	0
247	The use of selective estrogen receptor modulators in the treatment of menopausal women with schizophrenia. Acta Neuropsychiatrica, 2006, 18, 258-258.	1.0	O
248	Response to Anandarajan et al.: Manic exacerbation induced by nicotine patch. Australian and New Zealand Journal of Psychiatry, 2012, 46, 484-485.	1.3	0
249	Psychotropic medication in pregnancy. Medical Journal of Australia, 2013, 199, 661-661.	0.8	0
250	A balancing act: Clozapine adjustment in smokers. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1072-1072.	1.3	0
251	Seguridad de los antipsicóticos atÃpicos en el embarazo. Psiquiatria Biologica, 2016, 23, 23-28.	0.0	O
252	Pharmacogenomics in psychiatry – Clinical innovation utilised by the Therapeutic Goods Administration and Food and Drug Administration. Australian and New Zealand Journal of Psychiatry, 2017, 51, 93-94.	1.3	0

#	Article	IF	CITATIONS
253	Premenstrual dysphoric disorder and its association with complex trauma disorder: Three cases. Australian and New Zealand Journal of Psychiatry, 2018, 52, 904-905.	1.3	0
254	Antipsychotics in Pregnancy. , 2019, , 115-167.		0
255	Somatic symptoms: A form of grandiose delusions in manic disorder?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 323-323.	1.3	0
256	Impact of childhood exogenous hormones on mood. Australian and New Zealand Journal of Psychiatry, 2020, 54, 437-438.	1.3	0
257	Diagnostic overlap: Complex post-traumatic stress disorder and borderline personality disorder. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110347.	1.3	0
258	Assessment of cannabis use in schizophrenia, baseline results from the scap study. Australian and New Zealand Journal of Psychiatry, 2000, 34, A56-A56.	1.3	0
259	The clinical needs of women with schizophrenia. , 2012, , 183-201.		O
260	Raloxifene May Have Further Benefits in Women on Hemodialysis. International Journal of Endocrinology and Metabolism, 2012, 10, 644-5.	0.3	0
261	The physical symptoms of polycystic ovarian syndrome exacerbate the mental health symptoms of borderline personality disorder. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110625.	1.3	0
262	The need to take a trauma history in the acute psychiatry inpatient setting. Australian and New Zealand Journal of Psychiatry, 2022, , 000486742210970.	1.3	O